iSpecimen (ISPC) investor relations material

Company overview and business model

• Operates a technology-driven online marketplace connecting life science researchers with healthcare providers for human biospecimens and associated data, streamlining procurement for research and development.

• Revenue is generated by procuring specimens from a global network of healthcare providers and distributing them to research clients, with revenue sharing back to suppliers.

• The platform supports a wide range of biospecimen types, including remnant and research-use-only biofluids, tissues, and hematopoietic stem and immune cells.

• The supply network spans 14 countries and includes clinical labs, pathology labs, biorepositories, blood donor centers, cadaveric donation centers, and clinical research centers.

• Customers include biopharmaceutical companies, diagnostic firms, and government/academic institutions, with over 219,000 specimens distributed to 23 countries as of March 31, 2026.

Financial performance and metrics

• Reported net losses of $10.5 million in 2025 and $2.3 million for the three months ended March 31, 2026, with an accumulated deficit of $84.6 million as of March 31, 2026.

• Revenue for the three months ended March 31, 2026, was $1.9 million, compared to $2.7 million for the same period in 2025.

• Cash balance as of March 31, 2026, was $2.8 million, with pro forma cash of $5.2 million after the offering.

• Revenue is highly concentrated, with one customer accounting for 54% of revenue in Q1 2026.

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds of approximately $4.68 million (assuming full subscription) will be used for placement agent fees, offering expenses, outstanding debt, potential acquisitions, marketing and advertising (up to $1.1 million to IR Agency LLC), and general corporate and working capital purposes.

• Management has broad discretion over the use of proceeds, and actual allocations may vary depending on the amount raised.

• Proceeds are expected to fund operations for at least seven months post-offering.